Regenxbio (RGNX) Free Cash Flow (2014 - 2025)

Regenxbio's Free Cash Flow history runs 12 years deep, the most recent figure standing at -$51.3 million for Q4 2025.

• In Q4 2025, Free Cash Flow fell 56.78% year-over-year to -$51.3 million; the TTM figure through Dec 2025 stood at -$124.9 million (up 28.88% YoY), while the FY2025 annual figure was -$124.9 million, up 28.88% from the prior year.
• Free Cash Flow was -$51.3 million for Q4 2025 at Regenxbio, up from -$56.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $326.9 million in Q4 2021 to a low of -$85.7 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$31.6 million across 5 years, with a median of -$51.1 million in 2023.
• Biggest YoY gain for Free Cash Flow was 2485.08% in 2021; the steepest drop was 125.7% in 2021.
• A 5-year view of Free Cash Flow shows it stood at $326.9 million in 2021, then sank by 113.72% to -$44.8 million in 2022, then rose by 6.59% to -$41.9 million in 2023, then advanced by 21.92% to -$32.7 million in 2024, then sank by 56.78% to -$51.3 million in 2025.
• The last three Free Cash Flow figures came in at -$51.3 million (Q4 2025), -$56.5 million (Q3 2025), and -$49.7 million (Q2 2025), per Business Quant data.